You might want to read the press release VRTX just put out. They have 25,000 people on the HEP C drug now and 9 other drugs in development. It seems the launch was "Highly Successful" in Q4. They are also planning to launch Kalydeco in April and are expanding the drug to other mutations. The company now expects significant growth in cash flows for 2012. This could really be big now!
All I see now is competition lining up although some are still in Phase 1 and others in phase 2. My concern is that the 2012 revenue estimates for incivek were cut from 2.2 billion to 1.8 billion. Last time I read was now estimated at 1.4 billion. This quarter revenue will not be great because of the holidays. This coming quarter will indicate if the momentum is going to pick up or not. It is unfortunate that VRTX is now trying to catch up with the competition for the new treatment. I wonder if VRTX is one of the bidders. Now that GILD and BMY are out as buyers, who is left as potential buyers for ACHN, IBIX or even VRTX?
i have a feeling between ACHN, INHX, VRUS, IDIX, there's too much competition now for VRTX. i'm def. no scientist, but i think investorz are feeling the small cap companies technology is superior to VRTX older shyt.
the irony is VRTX is the only one with an actual product with sales! i guess all these large caps just want the smaller ones technology, they don't care wether the drug is approved or not. weird.
Drug giant Bristol-Myers Squibb Co. announced a deal to buy hepatitis C drug developer Inhibitex Inc. for $26 a share, or more than $2 billion.
The all-cash deal would pay Inhibitex a whopping 163% premium to its Friday closing price.
Inhibitex makes drugs for infectious diseases, including bacterial and viral infections such as shingles and chronic hepatitis C.
Shares of Inhibitex closed Friday at $9.87 a share, giving the company a market capitalization of roughly $773 million.
Analysts have suggested that a hepatitis C drug maker like Inhibitex could be a takeover target, especially after Gilead Scienes Inc. agreed in November to buy Pharmasset Inc. for about $11 billion.
Pharmasset and Inhibitex are among the companies that have hepatitis C drugs in development. Treatment for hepatitis C, a disease of the liver, are considered lucrative because the disease is prevalent in large sections of the global population.
Write to Anupreeta Das at email@example.com and Gina Chon at firstname.lastname@example.org
The question is: what does this mean for Vertex? There are two ways to look at it. First, one might say this is another bet against Vertex, just like Gilead's purchase of Pharmasset. And Inhibitex's hep C drugs should be even more likely to succeed now with Bristol Myers backing. The other way to look at it (the way I see it) is this represents further recognition of the importance of the hep C market, which Vertex currently dominates. Not only does Vertex own the most valuable hep C drug on the market (Incivek), but it has VX-222 in clinical trials for an all oral hep C regimen and two nucleosides entering clinical trials. If inhibitex is worth more than $2 billion, then Vertex must be worth at least $20 billion given the drugs it has for hep C and all the other great non-hep C drugs in Vertex's pipeline.